Actively Recruiting
Phase II Study of Serplulimab Plus Chemotherapy as Conversion Treatment for Adults With Stage IIIB-IVA Oligometastatic Non-Small Cell Lung Cancer
Led by Zhejiang University · Updated on 2023-07-17
49
Participants Needed
1
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of Serplulimab combined with chemotherapy as a conversion treatment for patients with stage IIIB-IVA oligometastatic non-small cell lung cancer NSCLC. This phase II, single-arm, open-label trial aims to determine how well this treatment can convert unresectable tumors into ones that can be surgically removed, and to assess progression-free survival and overall survival rates. The study also includes analysis to identify biomarkers that may predict treatment response. Participants with unresectable NSCLC will receive 3 to 4 cycles of Serplulimab plus chemotherapy every three weeks. The chemotherapy regimen includes carboplatin and either pemetrexed or nab-paclitaxel depending on cancer type. After this induction treatment, patients suitable for surgery will undergo curative pneumonectomy, while metastatic lesions may be treated with locoregional ablative therapies. Following surgery, maintenance treatment with PD-1 antibody will continue every three weeks for up to 12 months or until disease progression. During the study, participants will be closely monitored with evaluations including tumor response assessments up to 16 weeks and survival follow-up for up to five years. Researchers will measure outcomes such as the rate of tumors becoming resectable, progression-free survival at one year, major pathological response, pathological complete response, and overall survival. The study involves comprehensive clinical assessments and safety monitoring throughout the treatment and follow-up periods.
CONDITIONS
Brief Title
A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC
Research Team
P
Peng Zhao, MD
J
Jian Hu, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here